Endocrine resistance – a major cause of breast cancer deaths – can be underpinned by an epigenetic change called DNA methylation, researchers at the Garvan Institute of Medical Research have ...

In some cases, HR-positive/HER2-negative breast cancers may over time become resistant to endocrine therapy. This can occur through mutations in the estrogen receptor ...

Treatment Algorithms for Hormone Receptor-Positive Advanced Breast Cancer: Applying the Results from Recent Clinical Trials into Daily Practice—Insights, Limitations, and Moving Forward Treating ...

The evERA breast cancer trial marks a turning point for some patients with a specific type of advanced breast cancer known as ...

Analysis of AKR1B10 levels among various groups of breast cancer patients. Functional cell profiling (FCP) of ~100,000 CTCs from multiple cancer types identifies morphologically distinguishable CTC ...

The combination of CDK4/6 inhibitors with endocrine therapy is the standard of care for patients with estrogen receptor-positive (ER+) and HER2-negative (ER+/HER2-) metastatic breast cancer. However, ...

In the CAPItello-291 trial of capivasertib plus fulvestrant, 73% of patients had already received a CDK4/6 inhibitor. As ...

Olema Pharmaceuticals (OLMA) earns a "Strong Buy" rating, driven by advancing palazestrant for 1st-line ER+/HER2- metastatic ...

First pivotal trial to use a circulating tumor DNA (ctDNA)-guided approach to detect and treat emerging resistance in 1st-line therapy ahead of disease progression in breast cancer Trial showed ...

Epigenome remodeling, including widespread changes to DNA methylation and 3D chromatin structure, is increasingly recognized as an important mechanism of gene deregulation in cancer. For example, at ...